NAGE

MKT CAP:$397M

Niagen Bioscience Inc

Market Cap

$397M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.76-$1.49 (-23.84%)

Apr 21, 2026

Company Details

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

CEO

Robert N. Fried

IPO Date

Jun 24, 2015

Website

www.niagenbioscience.com

Key Metrics TTM

Revenue

$129M

+29.9% YoY

Net Income

$17M

EPS (Diluted)

$0.20

Free Cash Flow

$13M

Revenue / Share

$1.53

Gross Margin

64.3%

Operating Margin

11.0%

Net Margin

13.4%

FCF Margin

10.2%

P/S

3.1x

P/E

22.8x

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Dec 30, 2025

$129M+29.9%EPS $0.20

Q4 2025

Dec 30, 2025

$34M+16.2%EPS $0.05

Q3 2025

Sep 29, 2025

$34M+32.9%EPS $0.05

Q2 2025

Jun 30, 2025

$31M+36.8%EPS $0.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$17M	$11M	-$8M
Q2 22	$17M	$10M	-$6M
Q3 22	$17M	$10M	-$3M
Q4 22	$21M	$12M	-$1M
Q1 23	$23M	$14M	-$2M
Q2 23	$20M	$12M	-$2M
Q3 23	$19M	$12M	-$1M
Q4 23	$21M	$13M	-$168.0K
Q1 24	$22M	$13M	-$731.0K
Q2 24	$23M	$14M	-$256.0K
Q3 24	$26M	$16M	$2M
Q4 24	$29M	$18M	$7M
Q1 25	$30M	$19M	$5M
Q2 25	$31M	$20M	$3M
Q3 25	$34M	$22M	$4M
Q4 25	$34M	$22M	$2M

Valuation

Quarter	P/S	P/E
Q1 22	5.7x	—
Q2 22	5.7x	—
Q3 22	5.8x	—
Q4 22	5.5x	—
Q1 23	5.1x	—
Q2 23	4.9x	—
Q3 23	4.8x	—
Q4 23	4.7x	—
Q1 24	4.8x	—
Q2 24	4.6x	—
Q3 24	4.3x	267.2x
Q4 24	4.0x	46.4x
Q1 25	3.7x	28.1x
Q2 25	3.4x	22.4x
Q3 25	3.2x	19.4x
Q4 25	3.1x	22.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$7M	-$7M
Q2 22	-$4M	-$4M
Q3 22	-$4M	-$4M
Q4 22	-$328.0K	-$500.0K
Q1 23	$3M	$3M
Q2 23	$3M	$3M
Q3 23	$396.0K	$370.0K
Q4 23	$649.0K	$628.0K
Q1 24	$295.0K	$254.0K
Q2 24	-$264.0K	-$276.0K
Q3 24	$3M	$3M
Q4 24	$9M	$9M
Q1 25	$8M	$8M
Q2 25	$1M	$1M
Q3 25	$4M	$4M
Q4 25	$624.0K	$523.0K

Capital Expenditures

Quarter	CapEx
Q1 22	$25.0K
Q2 22	$85.0K
Q3 22	$52.0K
Q4 22	$172.0K
Q1 23	$91.0K
Q2 23	$10.0K
Q3 23	$26.0K
Q4 23	$21.0K
Q1 24	$41.0K
Q2 24	$12.0K
Q3 24	$41.0K
Q4 24	$69.0K
Q1 25	$32.0K
Q2 25	$135.0K
Q3 25	$24.0K
Q4 25	$101.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+17.5%	+13.4%
Q2 22	-5.5%	-0.6%
Q3 22	-1.4%	-23.0%
Q4 22	+18.2%	-2.8%
Q1 23	+30.7%	-1.9%
Q2 23	+21.5%	-2.1%
Q3 23	+14.3%	+2.6%
Q4 23	+1.0%	-4.8%
Q1 24	-1.8%	-6.7%
Q2 24	+11.9%	+1.6%
Q3 24	+31.2%	+16.2%
Q4 24	+37.4%	+3.0%
Q1 25	+37.6%	+12.3%
Q2 25	+36.8%	+21.5%
Q3 25	+32.9%	+24.1%
Q4 25	+16.2%	+44.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	10.9%
Q2 22	$1M	7.7%
Q3 22	$1M	7.2%
Q4 22	$1M	6.3%
Q1 23	$1M	5.6%
Q2 23	$1M	6.5%
Q3 23	$1M	5.7%
Q4 23	$1M	4.9%
Q1 24	$984.0K	4.4%
Q2 24	$1M	5.2%
Q3 24	$735.0K	2.9%
Q4 24	$752.0K	2.6%
Q1 25	$1M	3.5%
Q2 25	$1M	4.8%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$1M	$9M	$8M	—
Q2 22	$1M	$7M	$8M	—
Q3 22	$1M	$6M	$6M	—
Q4 22	$1M	$6M	$6M	—
Q1 23	$1M	$6M	$8M	—
Q2 23	$1M	$7M	$6M	—
Q3 23	$1M	$6M	$6M	—
Q4 23	$1M	$5M	$7M	—
Q1 24	$2M	$5M	$7M	—
Q2 24	$1M	$6M	$7M	—
Q3 24	$1M	$6M	$7M	—
Q4 24	$1M	$1M	$9M	—
Q1 25	$1M	$5M	$8M	—
Q2 25	$2M	$7M	$8M	—
Q3 25	$2M	$7M	$9M	—
Q4 25	$2M	—	—	$18M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$21M	$0	$21M
Q2 22	$17M	$0	$17M
Q3 22	$13M	$0	$13M
Q4 22	$20M	$0	$20M
Q1 23	$23M	$0	$23M
Q2 23	$26M	$0	$26M
Q3 23	$27M	$0	$27M
Q4 23	$27M	$0	$27M
Q1 24	$27M	$0	$27M
Q2 24	$28M	$0	$28M
Q3 24	$32M	$0	$32M
Q4 24	$45M	$0	$45M
Q1 25	$55M	$0	$55M
Q2 25	$60M	$0	$60M
Q3 25	$64M	$0	$64M
Q4 25	$65M	$0	$65M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	68M	+0.0%	+6.5%
Q2 22	68M	+0.0%	+0.5%
Q3 22	68M	+0.0%	+0.2%
Q4 22	74M	+8.1%	+8.2%
Q1 23	75M	+1.2%	+9.5%
Q2 23	75M	+0.2%	+9.7%
Q3 23	75M	+0.1%	+9.8%
Q4 23	75M	+0.1%	+1.7%
Q1 24	75M	+0.2%	+0.6%
Q2 24	76M	+0.4%	+0.8%
Q3 24	78M	+2.9%	+3.6%
Q4 24	82M	+5.0%	+8.8%
Q1 25	83M	+1.9%	+10.6%
Q2 25	86M	+3.6%	+14.1%
Q3 25	87M	+0.4%	+11.4%
Q4 25	84M	-2.5%	+3.4%

Shares Outstanding